Gain of chromosome 8q: A potential prognostic marker in resectable adenocarcinoma of the pancreas?

Annals of Surgical Oncology

Volumn 14, Issue 4, 2007, Pages 1327-1335

  Schleicher, Christina ^a   Poremba, Christopher ^b   Wolters, Heiner ^a   Schäfer, Karl Ludwig ^b   Senninger, Norbert ^a   Colombo Benkmann, Mario ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

CGH; Chromosome 8q; Comparative genomic hybridization; Cytogenetics; Pancreatic carcinoma

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 18P; CHROMOSOME 18Q; CHROMOSOME 3Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME MICRODISSECTION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ISOLATION; FEMALE; GENETIC MARKER; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; NICK END LABELING; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STANDARD; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 8; DNA; FEMALE; GENE AMPLIFICATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34047200348     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9113-x     Document Type: Article

References (46)

1. Greenlee RT, Hill-Hamon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51:15-36.
2. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999; 117:1464-84.
3. Hruban RH, Offerhaus GJ, Kern SE, Goggins M, Wilentz RE, Yeo CJ. Tumor-suppressor genes in pancreatic cancer. J Hepato-Biliary-Pancreatic- Surg 1998; 5:383-91.
4. Blanck HM, Tolbert PE, Hoppin JA. Patterns of genetic alterations in pancreatic cancer: a pooled anaylsis. Environ Mol Mutagen 1999; 33:111-22.
5. Day JD, Digiuseppe JA, Yeo C, et al. Imunnohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; 27:119-24.
6. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21:139-46.
7. von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000; 119:1358-72.
8. Gorunova L, Höglund M, Andren-Sandberg A, et al. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 1998; 23:81-99.
9. Ghadimi BM, Schröck E, Walker RL, et al. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999; 154:525-36.
10. Schleger C, Arens N, Zentgraf H, Bleyl U, Verbeke C. Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH). J Pathol 2000; 191:27-32.
11. Solinas-Toldo S, Wallrapp C, Müller-Pilsch F, Bentz M, Gress T, Lichter P. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 1996; 56:3803-7.
12. Mahlamäki EH, Höglund M, Gorunova L, et al. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer 1997; 20:383-91.
13. Mahlamäki EH, Bärlund M, Tanner M, et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer. 2002; 35:353-8.
14. Heidenblad M, Jonson T, Mahlamäki EH, et al. Detailed genomic mapping and expression analysis of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. Genes Chromosomes Cancer 2002; 34:211-33.
15. Tirado CA, Sandberg AA, Stone JF. Identification of a novel amplicon at 1q31 in pancreatic cancer cell lines. Cancer Genet Cytogenet 1999; 113:110-4.
16. Fukushige S, Waldman FM, Kimura M, et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997; 19:161-9.
17. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways. J Pathol 1999; 187:396-402.
18. Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridisation for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994; 10:231-43.
19. Moch H, Presti JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996; 56:27-30.
20. Isola JJ, Kallioniemi OP, Chu LW, et al. Genetic aberrations detected by comparative genomic hybridisation predict outcome in node-negative breast cancer. Am J Pathol 1995; 147:905-11.
21. Sirivatanauksorn V, Sirivatanauksorn Y, Lemoine NR. Molecular Pattern of ductal pancreatic cancer. Langenbeck's Arch Surg 1998; 383:105-15.
22. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1998; 85:17-26.
23. Capuzzi D, Santoro E, Hauck WW, et al. FHIT expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 2000; 88:24-34.
24. Guo Z, Johansson SL, Rhim JSl, Vishwanatha JK. Fragile histidine triad gene expression in primary prostate cancer and in an in vivo model. Prostate 2000; 43:101-10.
25. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 2000; 60:1049-53.
26. Sorio C, Baron A, Orlandini S, et al. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 1999; 59:1308-14.
27. Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and apoptosis in human pancreatic cancer. Cancer Res 2001; 61:4827-36.
28. Gopalakrishnan VK, Banerjee AG, Vishwanatha JK. Effect of FHIT gene replacement in growth, cell cycle and apoptosis in pancreatic cancer cells. Pancreatology 2003; 3:293-302.
29. Gruber SB, Petersen GM. Cancer risk in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 2002; 94(18):1344-5.
30. Birnbaum D, Adelaide J, Popovici C, Charafe-Jauffret E, Mozziconacci MJ, Chaffanet M. Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncol 2003; 4:639-42.
31. Bookstein R, Boya GS, MacGrogan D, Levy A, Isaacs WB. Tumor-suppressor genes in prostatic oncogenesis: a positional approach. Br J Urol 1997; 79(Suppl 1):28-36.
32. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor rececptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002; 9:633-40.
33. Seibold S, Rudroff C, Weber M, Galle J, Wanner C, Marx M. Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J 2003; 17:1180-2.
34. Tarkkanen M, Elomaa I, Blomqvist C, et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. In J Cancer 1999; 84:114-21.
35. Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridisation. Cancer Res 1997; 57:2860-4.
36. Van Dekken H, Alers JC, Damen I, et al. Genetic evaluation of localized prostate cancer in a cohort of orty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 2003; 83:789-96.
37. Alers JC, Rochat J, Krijtenburg PJ, et al. Identification of genetic markers for prostate cancer progression. Lab Invest 2000; 80:931-42.
38. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms and clinical significance. Mod Pathol 2002; 15:462-9.
39. Saramäki O, Willi N, Bratt O, et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 2001; 159:2089-94.
40. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK 2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003; 38:1242-9.
41. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61:4320-4.
42. Hiraoka K, Hida Y, Miyamoto M, et al. High expression of tumor-associated antigen RCAS1 in panceatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 2002; 99:418-23.
43. Su JM, Gui L, Zhou YP, Zha XL. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World J Gastroenterol 2002; 4:613-8.
44. Stagge V, Seufferlein T, Dürschmied D, Menke A, Adler G, Beil M. Integrin-mediated differentiation of a pancreatic carcinoma cell line is independent of FAK or MAPK activation levels. Pancreas 2001; 23:236-45.
45. Garnis C, Coe BP, Ishkanian A, Zhang L, Rosin MP, Lam WL. Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 2004; 39:93-8.
46. Beger HG, Poch B, Schwarz M, Gansauge F. Pancreatic cancer. The relative importance of neoadjuvant therapy. Chirurg 2003; 74:202-7.